Neurontin is an anticonvulsant indicated for use as an adjunctive therapy in the treatment of partial seizures in adults with epilepsy. This newly approved oral solution form of the drug has bioequivalence to the capsule form of the Neurontin, which was approved in January 1999. The two dosage forms have the same indications.
Neurontin may be taken with or without food.
If you take antacids (such as Maalox or Mylanta), you should wait at least two hours after antacid use before taking gabapentin.
705 adults with partial seizures were patients in clinical studies. Previous to clinical trials, all of these patients had at least 4 partial seizures a month, despite the use of one or more antiepileptic drugs. In three multicenter, placebo-controlled clinical trials, Neurontin was administered concurrently with the existing therapy. Reduction of frequency of partial seizures was significantly reduced in patients taking Neurontin 1200 mg/day, compared to placebo.
In a second study, patients taking 1200 mg/day Neurontin had greater reduction in seizure frequency than did those taking the placebo, however the difference was not statistically significant. The same was the case for 600 mg/day of Neurontin. On the other hand, 1800 mg/day yielded significantly greater reduction in seizure frequency than placebo.
Several studies also indicated that Neurontin was significantly more effective than placebo in preventing secondarily generalized tonic-clonic seizures.
In general, higher doses of Neurontin yielded greater reduction in frequency of seizures.
In clinical studies the most common side effects associated with Neurontin were:
The above side effects reportedly lasted approximately 2 weeks within clinical trials.
During postmarketing development of Neurontin, 8 sudden and unexplained deaths were recorded among 2203 patients.
The mechanism by which gabapentin exerts its anticonvulsant action is unknown, but in animal test systems designed to detect anticonvulsant activity, gabapentin prevents seizures as do other marketed anticonvulsants. Gabapentin exhibits antiseizure activity in mice and rats in both the maximal electroshock and pentylenetetrazole seizure models and other preclinical models (e.g., strains with genetic epilepsy, etc.). The relevance of these models to human epilepsy is not known.
Gabapentin is structurally related to the neurotransmitter GABA (gamma aminobutyric acid) but it does not interact with GABA receptors, it is not metabolically into GABA or a GABA agonist, and it is not an inhibitor of GABA uptake or degradation… (From FDA Label)
Visit the Parke-Davis Pharmaceuticals web site, www.parke-davis.com, to learn more about Neurontin and about other products, research, and services provided by the company that developed this drug.
For more information about epilepsy, visit the official web site of the Epilepsy Foundation, a non-profit volunteer agency devoted to research, education, advocacy, and services in the community for people with epilepsy and their families: www.efa.org
This is what the Epilepsy Foundation says to do and not to do if you encounter a person having an epileptic seizure:
What To Do:
What Not To Do: